This finding is relevant given that analyses of real‐world cohorts have shown that antiviral treatment leading to early ALT normalisation within 12 months is associated with a lower risk of hepatic events (including HCC) in patients with CHB [31, 32, 33]. This evidence concerns the gene GPT and hepatocellular carcinoma.